• 1
    Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 3536.
  • 2
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 2927.
  • 3
    Feagan BG, Fedorak RN, Irving EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000; 342: 162732.
  • 4
    Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001; 15: 3544.
  • 5
    Lémann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95: 17304.
  • 6
    Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 6937.
  • 7
    Vandell AG, DiPiro JT. Low-dose methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy 2002; 22: 61320.
  • 8
    Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic-active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 22039.
  • 9
    Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind placebo-controlled trial. Hepatogastroenterology 1999; 46: 17249.
  • 10
    Oguey D, Kolliker F, Gerber NJ, et al. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 6114.
  • 11
    Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 18459.
  • 12
    Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 8990.
  • 13
    Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994; 121: 83341.
  • 14
    Kozarek RA. Methotrexate for refractory Crohn's disease: preliminary answers to definite questions. Mayo Clin Proc 1996; 71: 1045.
  • 15
    Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folate and antifolates. Semin Oncol 1999; 26(S6): 1123.
  • 16
    Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 51230.
  • 17
    Pesce MA, Bodourian DH. Evaluation of fluorescence polarization immunoassay procedure for quantitation of methotrexate. Ther Drug Monit 1986; 8: 11521.
  • 18
    Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Philadelphia: Williams & Wilkins, 1995.
  • 19
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 20
    Bannwarth B, Pehourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194210.
  • 21
    Edelman J, Biggs DF, Fakhreddin J, et al. Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 1984; 35: 3826.
  • 22
    Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 914.
  • 23
    Kremer JM, Petrillo GF, Hamilton RA. Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 1995; 22: 414.
  • 24
    Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998; 46: 36976.
  • 25
    Hamilton RA, Kremer JM. The effects of food on methotrexate absorption. J Rheumatol 1995; 22: 6302.
  • 26
    Herman RA, Veng-Pedersen P, Hoffman J, et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989; 78: 16571.
  • 27
    Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997; 11: 56973.
  • 28
    Crom WR, Evans WE. Methotrexate. In: EvansWE, SchentagJJ, JuskoWJ, eds. Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring, 3rd edn. Vancouver, Washington: Applied Therapeutics, Inc., 1992: 291–42.
  • 29
    Zeng H, Chen ZS, Belinsky MG, et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001; 61: 722532.
  • 30
    Lebbe C, Beyeler C, Gerber NJ, et al. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 4757.
  • 31
    Chladek J, Grim J, Martinkova J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002; 54: 14756.
  • 32
    Eksborg S, Albertioni F, Beck O, et al. Methotrexate in rheumatoid arthritis — a limited sampling strategy for estimation of the area under the plasma concentration versus time curve. Ther Drug Monit 1994; 16: 5603.